Ghent University Academic Bibliography

Ultra-deep sequencing and single cell multi-omics characterize measurable residual disease and identify therapy-survived clone in pediatric acute myeloid leukemia

Borhan R. R Saeed, Anastasia Saboli, Anna Rehammar, Adam Molnar, Erik Delsing Malmberg, Barbara Depreter, Giti Shah Barkhordar, Barbara De Moerloose (UGent) , Tim Lammens (UGent) , Lars Palmqvist, et al.

(2024) BLOOD. In Blood 144(Supplement 1). p.4994-4995

Add to list

Nidogen-1, a novel player in KMT2A-rearranged pediatric acute myeloid leukemia patients, expressed in the leukemic stem cell

Jolien Vanhooren (UGent) , Larissa Deneweth (UGent) , Luca Pagliaro, Zhiyao Ren (UGent) , Barbara Depreter, Mattias Hofmans (UGent) , Barbara De Moerloose (UGent) and Tim Lammens (UGent)

(2024) BLOOD. In Blood 144(Supplement 1). p.6134-6135

Add to list

Journal Article
A1
open access

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma : ELARA trial update

Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, et al.

(2024) BLOOD. 143(17). p.1713-1725

Add to list

Domain specificity of anti-prothrombin antibodies that express lupus anticoagulant activity

Rachel Gehlen, Tessa Noordermeer, Arne Vandevelde (UGent) , Walid Chayoua, Marisa Ninivaggi, Romy De Laat-Kremers, Mark Roest, Philip G. De Groot, Katrien Devreese (UGent) , Rolf T. Urbanus, et al.

(2023) BLOOD. In Blood 142(Supplement 1). p.5529-5530

Add to list

A phase 1 study of PIT565, a first-in-class, anti-CD3, anti-CD19, anti-CD2 trispecific antibody in patients with relapsed and/or refractory B-Cell malignancies

Irit Avivi Mazza, Pere Barba, Junichiro Yuda, Maria Lia Palomba, Juan Pablo Alderuccio, Ciel De Vriendt (UGent) , Paolo Corradini, Francesca Lorraine Wei Inng Lim, Pier Luigi Zinzani, Nitin Jain, et al.

(2023) BLOOD. In Blood 142(Supplement 1). p.3099-3101

Add to list

The phase 2 CARTITUDE-2 trial : updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B)

Jens Hillengass, Adam D. Cohen, Mounzer E. Agha, Michel Delforge, Tessa Kerre (UGent) , Wilfried Roeloffzen, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab, et al.

(2023) BLOOD. In Blood 142(Supplement 1). p.1021-1024

Add to list

Englumafusp alfa (CD19-4-1BBL) and glofitamab combination in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL) : biomarker results from a phase I dose-escalation trial

Koorosh Korfi, Ailsa Christiansen, Zhiwen Jiang, Sabine Wilson, Samuel Tracy, Annika Blank, Sylvia Herter, Natalie Dimier, Bruno Gomes, Pablo Umana, et al.

(2023) BLOOD. In Blood 142(Supplement 1). p.3017-3019

Add to list

Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in Belgium after 4 years

Kirsten Saevels, Sylvia Snauwaert, Gaeten Vanstralen, Marc Andre, Fritz Offner (UGent) , Ariane Maes, Marjolein Lahaye and Ann Janssens

(2023) BLOOD. In Blood 142(Supplement 1). p.6550-6552

Add to list

Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel : phase 2 Elara 3-year follow-up

Stephen J. Schuster, Nathan Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie L. Popplewell, Julio C. Chavez, Emmanuel Bachy, et al.

(2023) BLOOD. In Blood 142(Supplement 1). p.601-605

Add to list

Single ascending doses of REGN7999, a monoclonal antibody inhibitor of TMPRSS6, increase serum hepcidin and cause deep, sustained reductions in serum iron in healthy human volunteers

Sylvie Rottey (UGent) , Nikhil Singh, Emily Labriola-Tompkins, Heinrich E Lob, Kusha Mohammadi, Hazem Hassan, Lorna Farrelly, Swati Duggal, Harvey Chin, Sarah Hatsell, et al.

(2023) BLOOD. In Blood 142(Supplement 1). p.3841-3842

Academic Bibliography

Ultra-deep sequencing and single cell multi-omics characterize measurable residual disease and identify therapy-survived clone in pediatric acute myeloid leukemia

Nidogen-1, a novel player in KMT2A-rearranged pediatric acute myeloid leukemia patients, expressed in the leukemic stem cell

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma : ELARA trial update

Domain specificity of anti-prothrombin antibodies that express lupus anticoagulant activity

A phase 1 study of PIT565, a first-in-class, anti-CD3, anti-CD19, anti-CD2 trispecific antibody in patients with relapsed and/or refractory B-Cell malignancies

The phase 2 CARTITUDE-2 trial : updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B)

Englumafusp alfa (CD19-4-1BBL) and glofitamab combination in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL) : biomarker results from a phase I dose-escalation trial

Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in Belgium after 4 years

Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel : phase 2 Elara 3-year follow-up

Single ascending doses of REGN7999, a monoclonal antibody inhibitor of TMPRSS6, increase serum hepcidin and cause deep, sustained reductions in serum iron in healthy human volunteers

Contents

Support

Contact